Immunomodulators - Part A
- 1st Edition, Volume 151 - April 2, 2026
- Latest edition
- Editor: Rossen Donev
- Language: English
Immodulators, Volume 151 explores the pivotal role immodulators play in regulating immune responses for health and disease management. The book provides an in-depth overview of var… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
Immodulators, Volume 151 explores the pivotal role immodulators play in regulating immune responses for health and disease management. The book provides an in-depth overview of various classes of immunomodulatory agents, including biologics, small molecules, natural compounds, and synthetic drugs, examining their mechanisms of action and therapeutic applications. Chapters in this new release include Marine-Derived Polysaccharides and Peptides as Next-Generation Immunomodulators: Molecular Mechanisms, Therapeutic Potential, and Translational Challenges, Advances in Immunomodulation: From Dietary Influence to Computational Precision, iPSC-derived immunotherapy for Tau and Alzheimer's disease, and much more.
Additional sections cover Antibodies targeting amyloid-β and Tau oligomers in Alzheimer's Disease, Biosimilars: Antibody and Nanobody Based Therapeutic Approaches Towards Protein Misfolding Diseases, Immunomodulator drugs: mechanisms of action and systemic effects, Microbiome and microbial products as immunomodulators: implication for gastrointestinal cancers, Integration of Network pharmacology, docking, and dynamics analysis to investigate the immunomodulatory activity of Pongamia pinnata, Transcriptomic Insights into Epigenetic and Immunomodulatory Roles of Nuclear Histone Genes in Bladder Cancer: A bioinformatics Approach, Utilizing DREIMT Database for Drug Prioritization in Immunomodulatory Therapy for Psoriasis and Psoriatic Arthritis, and many additional topics.
Additional sections cover Antibodies targeting amyloid-β and Tau oligomers in Alzheimer's Disease, Biosimilars: Antibody and Nanobody Based Therapeutic Approaches Towards Protein Misfolding Diseases, Immunomodulator drugs: mechanisms of action and systemic effects, Microbiome and microbial products as immunomodulators: implication for gastrointestinal cancers, Integration of Network pharmacology, docking, and dynamics analysis to investigate the immunomodulatory activity of Pongamia pinnata, Transcriptomic Insights into Epigenetic and Immunomodulatory Roles of Nuclear Histone Genes in Bladder Cancer: A bioinformatics Approach, Utilizing DREIMT Database for Drug Prioritization in Immunomodulatory Therapy for Psoriasis and Psoriatic Arthritis, and many additional topics.
Key features
Key features
- Covers the fundamental principles of immunomodulation and the mechanisms by which immunomodulators influence the immune system
- Provides a detailed discussion of various classes, including biological, synthetic, natural, and small molecule immunomodulators
- Explains how immunomodulators work at cellular and molecular levels to modulate immune responses
Readership
Readership
Immunologists, Clinical researchers, Medical professionals, Pharmacologists
Table of contents
Table of contents
1. Marine-Derived Polysaccharides and Peptides as Next-Generation Immunomodulators: Molecular Mechanisms, Therapeutic Potential, and Translational Challenges
Selvaraj Chandrabose Sr.
2. Advances in Immunomodulation: From Dietary Influence to Computational Precision
Karthick Vasudevan, Prasanna Kumar Selvam and Supraja Mohan
3. iPSC-derived immunotherapy for Tau and Alzheimer's disease
Subashchandrabose Chinnathambi
4. Antibodies targeting amyloid-β and Tau oligomers in Alzheimer's Disease
Subashchandrabose Chinnathambi
5. Biosimilars: Antibody and Nanobody Based Therapeutic Approaches Towards Protein Misfolding Diseases
Subashchandrabose Chinnathambi and Nagaraj Rangappa
6. Immunomodulator drugs: mechanisms of action and systemic effects
Vijay Kumar Prajapati
7. Microbiome and microbial products as immunomodulators: implication for gastrointestinal cancers
Vijay Kumar Prajapati
8. Integration of Network pharmacology, docking, and dynamics analysis to investigate the immunomodulatory activity of Pongamia pinnata
George Priya Doss C
9. Transcriptomic Insights into Epigenetic and Immunomodulatory Roles of Nuclear Histone Genes in Bladder Cancer: A bioinformatics Approach
George Priya Doss C, Mangesh R, Santhosh Elavarasu, Insha Asheem, Nihla M, Udhaya Kumar and Sasikumar K
10. Utilizing DREIMT Database for Drug Prioritization in Immunomodulatory Therapy for Psoriasis and Psoriatic Arthritis
George Priya Doss C
11. Targeting Immune Modulation Genes in Mpox. A Therapeutic Approach Using Natural Compounds
George Priya Doss C
12. Identification of Common Hub Genes and Pathways in Systemic Lupus Erythematosus and Cervical Cancer Using Bioinformatics Approach
George Priya Doss C, Tamizhini Loganathan and Hatem Zayed
13. Transcriptomic Profiling Reveals Immune Pathway Dysregulation and Key Interferon-Responsive Genes in Systemic Lupus Erythematosus
Karthick Vasudevan, Prasanna Kumar Selvam and Supraja Mohan
14. TBC*
Edeildo Ferreira da Silva-Júnior
15. TBC*
Edeildo Ferreira da Silva-Júnior
16. Synthetic Immunomodulators: Revolutionizing Immunotherapy
Ajaz Ahmad Bhat
17. Therapeutics Immunotargets for Tauopathy
Subashchandrabose Chinnathambi
18. Antioxidants as immunomodulators for Tau and Amyloid-β in Alzheimer's disease
Subashchandrabose Chinnathambi
19. VISTA as a double-edged immune checkpoint molecule in cancer and autoimmunity
Sibel Kalyoncu Uzunlar
Selvaraj Chandrabose Sr.
2. Advances in Immunomodulation: From Dietary Influence to Computational Precision
Karthick Vasudevan, Prasanna Kumar Selvam and Supraja Mohan
3. iPSC-derived immunotherapy for Tau and Alzheimer's disease
Subashchandrabose Chinnathambi
4. Antibodies targeting amyloid-β and Tau oligomers in Alzheimer's Disease
Subashchandrabose Chinnathambi
5. Biosimilars: Antibody and Nanobody Based Therapeutic Approaches Towards Protein Misfolding Diseases
Subashchandrabose Chinnathambi and Nagaraj Rangappa
6. Immunomodulator drugs: mechanisms of action and systemic effects
Vijay Kumar Prajapati
7. Microbiome and microbial products as immunomodulators: implication for gastrointestinal cancers
Vijay Kumar Prajapati
8. Integration of Network pharmacology, docking, and dynamics analysis to investigate the immunomodulatory activity of Pongamia pinnata
George Priya Doss C
9. Transcriptomic Insights into Epigenetic and Immunomodulatory Roles of Nuclear Histone Genes in Bladder Cancer: A bioinformatics Approach
George Priya Doss C, Mangesh R, Santhosh Elavarasu, Insha Asheem, Nihla M, Udhaya Kumar and Sasikumar K
10. Utilizing DREIMT Database for Drug Prioritization in Immunomodulatory Therapy for Psoriasis and Psoriatic Arthritis
George Priya Doss C
11. Targeting Immune Modulation Genes in Mpox. A Therapeutic Approach Using Natural Compounds
George Priya Doss C
12. Identification of Common Hub Genes and Pathways in Systemic Lupus Erythematosus and Cervical Cancer Using Bioinformatics Approach
George Priya Doss C, Tamizhini Loganathan and Hatem Zayed
13. Transcriptomic Profiling Reveals Immune Pathway Dysregulation and Key Interferon-Responsive Genes in Systemic Lupus Erythematosus
Karthick Vasudevan, Prasanna Kumar Selvam and Supraja Mohan
14. TBC*
Edeildo Ferreira da Silva-Júnior
15. TBC*
Edeildo Ferreira da Silva-Júnior
16. Synthetic Immunomodulators: Revolutionizing Immunotherapy
Ajaz Ahmad Bhat
17. Therapeutics Immunotargets for Tauopathy
Subashchandrabose Chinnathambi
18. Antioxidants as immunomodulators for Tau and Amyloid-β in Alzheimer's disease
Subashchandrabose Chinnathambi
19. VISTA as a double-edged immune checkpoint molecule in cancer and autoimmunity
Sibel Kalyoncu Uzunlar
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 151
- Published: April 2, 2026
- Language: English
About the editor
About the editor
RD
Rossen Donev
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
Affiliations and expertise
Head of Research, MicroPharm Limited, UK